Arcutis Biotherapeutics (ARQT) to Release Earnings on Wednesday

Arcutis Biotherapeutics (NASDAQ:ARQT) is projected to release its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Arcutis Biotherapeutics to post earnings of $0.02 per share and revenue of $110.7940 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Arcutis Biotherapeutics Stock Performance

NASDAQ ARQT opened at $26.61 on Wednesday. The company has a market cap of $3.26 billion, a P/E ratio of -73.92 and a beta of 1.70. The company has a fifty day simple moving average of $27.52 and a 200 day simple moving average of $23.24. The company has a current ratio of 3.50, a quick ratio of 3.28 and a debt-to-equity ratio of 0.68. Arcutis Biotherapeutics has a 12-month low of $11.75 and a 12-month high of $31.77.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ARQT. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Arcutis Biotherapeutics in a report on Wednesday, October 29th. Mizuho lifted their price target on Arcutis Biotherapeutics from $32.00 to $37.00 and gave the company an “outperform” rating in a research note on Friday, November 28th. Zacks Research lowered Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen cut Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Arcutis Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $29.20.

Insider Activity at Arcutis Biotherapeutics

In other news, Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.05, for a total transaction of $250,500.00. Following the sale, the director directly owned 59,744 shares in the company, valued at $1,496,587.20. The trade was a 14.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Masaru Matsuda sold 40,638 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.28, for a total transaction of $1,027,328.64. Following the completion of the transaction, the insider directly owned 110,003 shares in the company, valued at $2,780,875.84. This trade represents a 26.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 216,460 shares of company stock valued at $6,063,314 in the last ninety days. Insiders own 9.40% of the company’s stock.

Institutional Trading of Arcutis Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its stake in Arcutis Biotherapeutics by 1,228.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company’s stock valued at $33,872,000 after acquiring an additional 1,078,546 shares during the last quarter. State Street Corp raised its holdings in shares of Arcutis Biotherapeutics by 18.2% in the 4th quarter. State Street Corp now owns 5,488,301 shares of the company’s stock worth $159,380,000 after purchasing an additional 846,986 shares during the period. Voloridge Investment Management LLC purchased a new position in Arcutis Biotherapeutics in the third quarter valued at approximately $15,711,000. Bank of America Corp DE grew its holdings in Arcutis Biotherapeutics by 133.5% during the second quarter. Bank of America Corp DE now owns 1,202,513 shares of the company’s stock valued at $16,859,000 after purchasing an additional 687,562 shares during the period. Finally, Nearwater Capital Markets Ltd bought a new position in Arcutis Biotherapeutics during the fourth quarter valued at $17,860,000.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.